AEGLEA BIOTHERAPEUTICS, INC.

901 S. MoPac Expressway

Barton Oaks Plaza One, Suite 250

Austin, TX 78746

May 25, 2017

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Suzanne Hayes

Assistant Director

Office of Healthcare and Insurance

Re: Aeglea BioTherapeutics, Inc.

Registration Statement on Form S-3

Filed May 1, 2017

File No. 333-217573

Via EDGAR - Acceleration Request

Requested Date: May 30, 2017

Requested Time: 4:30 p.m. Eastern Time

Ladies and Gentlemen:

Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,
AEGLEA BIOTHERAPEUTICS, INC.
By:	/s/ Charles N. York II
	Charles N. York II
	Chief Financial Officer

cc: David G. Lowe, Chief Executive Officer

Aeglea BioTherapeutics, Inc.

Robert A. Freedman, Esq.

Effie Toshav, Esq.

Fenwick & West LLP